sponsored
PatientsVille.com Logo

PatientsVille

Rivastigmine Medical Research Studies

Up-to-date List of Rivastigmine Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Rivastigmine Medical Research Studies

Rank Status Study
1 Recruiting Rivastigmine and Huperzine A as Treatments for Cocaine Dependence
Conditions: Cocaine Dependence;   Cocaine Addiction;   Cocaine Abuse;   Substance Abuse
Interventions: Drug: Placebo;   Drug: Rivastigmine 3 mg;   Drug: Huperzine A 0.4 mg;   Drug: Rivastigmine 6 mg;   Drug: Huperzine A 0.8 mg
Outcome Measures: The effects of Rivastigmine or huperzine A and cocaine on cardiovascular measures;   The effects of Rivastigmine or huperzine A and cocaine on subjective measures
2 Recruiting Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia
Condition: Alzheimer's Dementia
Intervention: Drug: ENA713
Outcome Measures: Tolerability of Rivastigmine switching from an oral capsule (3 mg b.i.d.) to a transdermal patch 5 cm2;   The changes in Mini-Mental Status Examination (MMSE) of patients with Alzheimer's disease treated with Exelon 5 cm2 Patch at Week 28 and Exelon 10 cm2 Patch at Week 52;   The changes in Alzheimer Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) of patients with Alzheimer's disease treated with Exelon 5 cm2 Patch at Week 28 and Exelon 10 cm2 Patch at Week 52;   The discontinuation rate due to the treatment switching from oral capsule to Rivastigmine patch treatment;   Percentage of patients successfully titrated to Rivastigmine patch 10 cm2
3 Not yet recruiting Brain Changes by Rivastigmine According to Butyrylcholinesterase Alleles
Condition: Alzheimer's Disease
Intervention: Drug: Rivastigmine
Outcome Measures: the mean changes of Standardized Uptake Values (SUVmean) in PET imaging;   the mean changes of serum BuChE activity between BuChE wild type and K-variant type;   the mean changes of cortical thickness in brain MRI;   the cognitive changes in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog);   the cognitive changes in Mini-Mental State Exam (MMSE);   the daily function changes by Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL);   the behavioural changes by Caregiver-Administered Neuropsychiatric Inventory (NPI);   the disease severity changes by Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) between BuChE wild type and K-variant type
4 Unknown  Study for the Tolerability of Exelon Patch (Rivastigmine) for Alzheimer's Disease (AD) Patients
Condition: Alzheimer's Disease
Intervention: Drug: Rivastigmine patch
Outcome Measures: Number of participants with adverse events;   Factors for the disuse of Rivastigmine patch
5 Recruiting Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI
Conditions: Traumatic Brain Injury;   Cognitive Impairment
Intervention: Drug: Rivastigmine Transdermal Patch
Outcome Measures: Impairment will be defined by memory impairments indexed by the Hopkins Verbal Learning Test-Revised (HVLT-R) total Trials 1-3;   To compare the effects of Rivastigmine transdermal patch with placebo using performance-based measures of functional capacity, cognitive functioning, mood, quality of life, and safety measures;   To assess longer-term efficacy and safety of Rivastigmine transdermal patch of double-blind treatment period
6 Unknown  Mild Cognitive Impairment in Parkinson's Disease
Conditions: Parkinson's Disease;   Mild Cognitive Impairment
Interventions: Drug: Exelon Patch (Rivastigmine transdermal system);   Drug: Placebo Patches
Outcome Measures: Alzheimer's Disease Cooperative Study- Clinical Global Impression Change (ADCS-CGIC);   Treatment Emergent Symptom Scale (TESS);   Montreal Cognitive Assessment (MoCA);   Mind Streams Global Assessment Battery (GAB);   Clinical Dementia Rating (CDR);   Functional Activities Questionnaire (FAQ);   Assessment of Daily Function Questionnaire;   Parkinson Disease Questionnaire (PDQ-8);   Gordon Diagnostic System (GDS);   Dementia Rating Scale (DRS-2);   Psychiatric Measures;   Measures of Parkinson's Disease Severity;   Everyday Cognition Battery (ECB) and Memory Acquisition-Transfer Task
7 Unknown  Efficacy Study for Treatment of Dementia in Progressive Supranuclear Palsy
Conditions: Progressive Supranuclear Palsy;   Dementia
Intervention: Drug: Rivastigmine
Outcome Measures: improvement in neuropsychological assessments for memory and executive function, e.g. tested by "Tower of London Test, CERAD Battery and Logical Memory Test (WMSR)";   changes in speech function and improvement of quality of life
8 Not yet recruiting Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson's Disease
Condition: Parkinson's Disease
Intervention: Drug: Rivastigmine
Outcome Measures: time to start with antipsychotic treatment for visual hallucinations;   motor control;   psychotic symptoms;   cognitive function;   mood disturbance;   daytime sleepiness;   cholinergic deficiency;   adverse events;   compliance;   disability;   caregiver burden;   care use
9 Not yet recruiting 16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients
Condition: Alzheimer's Disease
Intervention: Drug: Rivastigmine
Outcome Measures: Change From Baseline in the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog);   Mean Change From Baseline in the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) Score;   Change From Baseline in Mini-Mental State Examination (MMSE);   Mean Change From Baseline in Neuropsychiatric Inventory (NPI) Score;   Mean Change From Baseline in Caregiver Burden Inventory (CBI) Score;   Number of Participants Who Discontinued From the Stduy Due to Any Adverse Event (AE)
10 Recruiting Rivastigmine in the Management of Delirium
Condition: Delirium
Interventions: Drug: Rivastigmine transdermal patch;   Drug: placebo patch
Outcome Measures: Hospital length of stay from randomization to declaration by investigator (MD) that patient can leave acute care;   Percentage of patients with persistent delirium symptoms (DRS R-98 scale);   Percentage of patients with persistent delirium symptoms at day 30 (CAM scale);   Percentage of patients with a dementia diagnosis at 12 months (according to the DSM IV criteria)
11 Recruiting Cognitive Decline in Non-demented PD
Condition: Parkinson's Disease
Interventions: Drug: Strattera;   Drug: Exelon;   Other: Placebo
Outcome Measures: Attention network effects;   Quality of life;   Stroop Color Word Test;   Fatigue;   Depression;   Daytime sleepiness
12 Recruiting Treatment of Orthostatic Hypotension in Autonomic Failure
Conditions: Autonomic Failure;   Orthostatic Hypotension
Interventions: Drug: Atomoxetine;   Drug: Acarbose;   Drug: Pyridostigmine Bromide;   Drug: Yohimbine;   Drug: Midodrine HCl;   Drug: placebo;   Drug: Modafinil;   Drug: Octreotide;   Other: water intake;   Drug: Diphenhydramine Hydrochloride;   Drug: Ranitidine HCL;   Drug: Tranylcypromine;   Drug: Ergotamine/ Caffeine;   Drug: Celecoxib;   Drug: Pseudoephedrine;   Drug: Methylphenidate;   Drug: Indomethacin;   Drug: Ibuprofen;   Drug: Oxymetazoline 0.05% nasal solution;   Dietary Supplement: Bovril;   Drug: Acetazolamide;   Drug: Rivastigmine tartrate;   Drug: Carbidopa/levodopa;   Device: Inflatable abdominal binder;   Device: inflatable abdominal binder (sham)
Outcome Measures: Increase in seated systolic blood pressure 1-hr post drug compared to baseline.;   Increase in standing time 1-hr post drug compared to baseline
13 Recruiting Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease
Conditions: Alzheimer's Disease;   Dementia
Interventions: Drug: Cholinesterase Inhibitor;   Drug: Placebo
Outcome Measures: Clinician's Global Impression of Change (CGIC);   Number of total adverse events
14 Recruiting Comparative Research of Alzheimer's Disease Drugs
Conditions: Dementia;   Alzheimer's Disease
Interventions: Drug: Donepezil;   Drug: Galantamine;   Drug: Rivastigmine
Outcome Measures: Discontinuation and Adherence Rates;   Neuropsychiatric Inventory (NPI);   HABC Monitor
15 Recruiting A Genetic and Perfusion Study of Response to Cognitive Enhancers in Lewy Body Disease
Condition: Lewy Body Disease
Intervention: Drug: Cholinesterase Inhibitors (Rivastigmine, Aricept, Galantamine)
Outcome Measures: Change from baseline in perfusion brain SPECT at 6 months;   Change from baseline in neuropsychological assessment scores at 6 months;   Volumetric Brain MRI
16 Recruiting Use of Alternative Medicine in Patients With Dementia and Mild Cognitive Dysfunction
Conditions: Dementia;   Cognitive Impairment
Intervention:
Outcome Measures: Number of patients taking alternative medicines;   Numbers of potential and clinical relevant interactions;   The patient's subjective experiences with alternative medicines
17 Recruiting Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly
Conditions: Alzheimer Disease;   Mild Cognitive Impairment;   Delirium, Dementia, Amnestic, Cognitive Disorders
Intervention: Drug: Donepezil
Outcome Measures: Change over time in Selective Reminding Test (SRT) Scores;   Alzheimer's Disease Assessment Scale - Cognitive (ADAS-Cog);   Clinician's Interview Based Impression (CIBIC-plus);   Pfeffer Functional Activities Questionnaire (FAQ);   Measurement of Everyday Cognition (Ecog)
18 Unknown  Clinical Trial of Donepezil Between the Naive Group and the Switching Group
Conditions: Alzheimer's Disease;   Dementia
Intervention: Drug: donepezil
Outcome Measures: Alzheimer's Disease Assessment Scale-Cognitive, Korean version (ADAS-Cog-K);   Seoul Activities of Daily Living (S-ADL);   Seoul-Instrumental Activities of Daily Living (S-IADL);   Korean Neuropsychiatric Inventory (K-NPI)
19 Recruiting The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD
Conditions: Alzheimer Disease;   Dementia;   Brain Diseases;   Central Nervous System Diseases;   Nervous System Diseases;   Tauopathies;   Neurodegenerative Diseases;   Delirium, Dementia, Amnestic, Cognitive Disorders;   Mental Disorders
Intervention: Biological: NEUROSTEM®-AD
Outcome Measures: Safety;   Efficacy

These studies may lead to new treatments and are adding insight into Rivastigmine etiology and treatment.

A major focus of Rivastigmine research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Rivastigmine